Antiphospholipid syndrome: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 6
• BCMA 2
• JAK 1

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

No running funded project names this disease yet.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  HYDROxychloroquine in Syndrome Primary AntiPhospholipid

  NCT04275778· Assistance Publique - Hôpitaux de Paris· Updated 6 Apr 2026

  “The study was terminated following revisions to the diagnostic criteria defining the target pathology, which significantly impacted the study design”Registry text, quoted unchanged. Source

• Withdrawn

  Pregnancy and Medically Assisted Conception in Rare Diseases

  NCT02450396· Assistance Publique - Hôpitaux de Paris· Updated 27 Mar 2026

  “Abandonment of the study project”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)

  NCT07172022· Hoffmann-La Roche· Updated 2 Mar 2026

  “The study was discontinued due to a strategic business/portfolio decision by the sponsor and was not related to any medical or safety issue.”Registry text, quoted unchanged. Source

• Terminated

  Telitacicept in Primary APS Patients

  NCT05078710· Peking Union Medical College Hospital· Updated 8 Jun 2025

  “There is no clear therapeutic effect among the enrolled patients for the time being.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

  NCT06371417· Chugai Pharmaceutical· Source

• Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

  NCT06723106· Chugai Pharmaceutical· Source

• A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)

  NCT07172022· Hoffmann-La Roche· Source

• Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients

  NCT07372170· Infanta Leonor University Hospital· Source

• Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

  NCT05646394· McMaster University· Source

• Hematological Disorders in EHPVO Patients

  NCT07108023· Rahab Nady· Source

• Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

  NCT05199909· Institute of Hematology & Blood Diseases Hospital, China· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.